Table 1.
Clinical characteristics of included studies.
| Frist author; Publish time; (No.) | Drug (dosage), manufacturer, | Country of trial | Trial | Male (n) | Female (n) | Age (years) | Hight (cm) | Weight (kg) | BMI (kg/m2) |
|---|---|---|---|---|---|---|---|---|---|
| Chen L. 2021 (#1) | (1) Generic metformin (250 mg), Penglai Nuokang Pharmaceutical Co., Ltd., China; (2) Glycoran® (250 mg). Nippon Shinyaku CO., LTD., Japan. | China | Fasting | 24 | 8 | 28.0 ± 7.89 | 167.98 ± 8.28 | 62.93 ± 7.22 | 22.31 ± 2.07 |
| Fed | 21 | 11 | 28.3 ± 8.56 | 167.44 ± 7.93 | 62.81 ± 6.94 | 22.42 ± 2.15 | |||
| Gao R. 2021 (#2) | (1) Generic metformin (250 mg), Harbin Zhenbao Pharmaceutical Co., Ltd. China; (2) Glycoran® (250 mg). Nippon Shinyaku CO., LTD., Japan. | China | Fasting | 14 | 10 | 33.83 ± 9.76 | 166.25 ± 6.86 | 67.82 ± 9.6 | 24.45 ± 2.26 |
| Fed | 16 | 8 | 35.88 ± 10.44 | 165.79 ± 9.13 | 64.73 ± 10.01 | 23.5 ± 2.43 | |||
| Huang X. 2020 (#3) | (1) Generic metformin (250 mg), Chongqing Kerui Pharmaceutical (Group) Co., LTD., China; (2) Glycoran® (250 mg). Nippon Shinyaku CO., LTD., Japan. | China | Fasting | 20 | 8 | 25.4 ± 6.4 | 164.57 ± 8.00 | 60.51 ± 7.41 | 22.3 ± 1.94 |
| Fed | 22 | 6 | 25.0 ± 4.7 | 165.21 ± 9.62 | 63.13 ± 9.84 | 23.02 ± 1.93 | |||
| Chen L. 2019 (#4) | (1) Generic metformin (250 mg), Shanxi Ante Bio-pharmaceutical Co., Ltd., China; (2) Glycoran® (250 mg). Nippon Shinyaku CO., LTD., Japan. | China | Fasting | 15 | 9 | 34.4 ± 8.0 | Not reported | Not reported | 23.46 ± 1.89 |
| Fed | 11 | 13 | 40.0 ± 8.1 | Not reported | Not reported | 24.05 ± 2.37 | |||
| Sun ML. To be published (#5, #6) | (1) Generic metformin (250 mg), Beijing Zhongxin Pharmaceutical Group Co., Ltd., China; (2) Glycoran® (250 mg), Nippon Shinyaku CO., LTD., Japan. | China | Fasting | 27 | 9 | 35.58 ± 10.55 | 166.97 ± 9.62 | 65.49 ± 9.79 | 23.42 ± 2.44 |
| Fed | 27 | 9 | 34.78 ± 9.44 | 166.55 ± 7.95 | 66.81 ± 9.43 | 24.06 ± 2.61 | |||
| Sun ML. 2021a, b (#7, #8) | (1) Generic metformin (850 mg), Guangdong Sinocorp pharmaceutical Co., Ltd. China; (2) Glucophage® (850 mg), the Merck UK corporate. | China | Fasting | 26 | 10 | 33.44 ± 8.62 | 166.38 ± 8.78 | 65.68 ± 10.38 | 23.65 ± 2.63 |
| Fed | 25 | 11 | 27.94 ± 6.35 | 165.94 ± 6.79 | 64.99 ± 9.62 | 23.55 ± 2.68 | |||
| Urban LE. 2018 (#9) | Glucophage® (850 mg), Bristol-Myers Squibb Co., USA. | Canada | Fasting + Fed | 12 | 12 | 47 ± 12 | 168 ± 8 | 84 ± 12 | 30 ± 3 |
| Sambol NC. 1996 (#10) | Metformin (850 mg), manufacturer was not reported. | USA | Fasting + Fed | 24 | 0 | 21–35 | NR | NR | NR |
Notes: BMI = body mass index. #, means the serial number of articles included in this study (Supplementary, Appendix 3).